Case Marks First Use of RenovoCath in Sarcoma, Showing Real World Potential Beyond Pancreatic Cancer for Expansion of Localized Delivery of Chemotherapy MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”). Sarcoma is a cancer that starts in the soft tissues or bones of the body. For this patient’s sarcoma case, CARTI is using RenovoRx’s RenovoCath device to deliver chemotherapy locally near the tumor rather than through traditional systemic intravenous...

DOVER, USA, Aug. 06, 2026 (GLOBE NEWSWIRE) — E-Power Inc. (“E-Power,” the “Company,” “we” or “our”) (NASDAQ: EPOW), a leading provider of AI Data Center (AIDC) microgrid solutions and advanced battery materials, today announced the closing of a private placement of 15,841,585 Class A ordinary shares of the Company at a purchase price of US$1.01 per share, for aggregate gross proceeds of approximately US$16.0 million, before deducting offering expenses payable by the Company. The Company entered into a subscription agreement with an investor on June 16, 2026, and the transaction closed on June 29, 2026. The Class A ordinary shares were issued to a single non-U.S. investor in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The transaction was approved by the Company’s board of directors. Key...

Six Additional U.S. Patent Applications Filed as Company Advances Texatron™ Development, Regulatory Initiatives, and Next Phase of Testing SOUTHLAKE, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTC: AMFN) (“American Fusion” or the “Company”), developer of the proprietary Texatron™ Fusion Engine™, continues to expand its intellectual property portfolio with the filing of six additional United States patent applications covering multiple aspects of the Texatron™ Fusion Engine™ platform while providing an update on several key corporate and engineering initiatives. The six additional patent applications bring the Company’s total number of U.S. patent applications filed to 82. Collectively, the applications continue American Fusion’s intellectual property strategy of...